Literature DB >> 23017648

Colonic inflammation in Parkinson's disease.

David Devos1, Thibaud Lebouvier, Bernard Lardeux, Mandy Biraud, Tiphaine Rouaud, Hélène Pouclet, Emmanuel Coron, Stanislas Bruley des Varannes, Philippe Naveilhan, Jean-Michel Nguyen, Michel Neunlist, Pascal Derkinderen.   

Abstract

Lewy pathology affects the gastrointestinal tract in Parkinson's disease (PD) and data from recent genetic studies suggest a link between PD and gut inflammation. We therefore undertook the present survey to investigate whether gastrointestinal inflammation occurs in PD patients. Nineteen PD patients and 14 age-matched healthy controls were included. For each PD patients, neurological and gastrointestinal symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III and the Rome III questionnaire, respectively and cumulative lifetime dose of L-dopa was calculated. Four biopsies were taken from the ascending colon during the course of a total colonoscopy in controls and PD patients. The mRNA expression levels of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon gamma, interleukin-6 and interleukin-1 beta) and glial marker (Glial fibrillary acidic protein, Sox-10 and S100-beta) were analyzed using real-time PCR in two-pooled biopsies. Immunohistochemical analysis was performed on the two remaining biopsies using antibodies against phosphorylated alpha-synuclein to detect Lewy pathology. The mRNA expression levels of pro-inflammatory cytokines as well as of two glial markers (Glial fibrillary acidic protein and Sox-10) were significantly elevated in the ascending colon of PD patients with respect to controls. The levels of tumor necrosis factor alpha, interferon gamma, interleukin-6, interleukin-1 beta and Sox-10 were negatively correlated with disease duration. By contrast, no correlations were found between the levels of pro-inflammatory cytokines or glial markers and disease severity, gastrointestinal symptoms or cumulative lifetime dose of L-dopa. There was no significant difference in the expression of pro-inflammatory cytokines or glial marker between patients with and without enteric Lewy pathology. Our findings provide evidence that enteric inflammation occurs in PD and further reinforce the role of peripheral inflammation in the initiation and/or the progression of the disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23017648     DOI: 10.1016/j.nbd.2012.09.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  177 in total

Review 1.  Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases.

Authors:  Fernando Ochoa-Cortes; Fabio Turco; Andromeda Linan-Rico; Suren Soghomonyan; Emmett Whitaker; Sven Wehner; Rosario Cuomo; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

Review 2.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

Review 3.  Microbiome, Immunomodulation, and the Neuronal System.

Authors:  Eric Marietta; Irina Horwath; Veena Taneja
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

4.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

5.  Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.

Authors:  Pablo Garrido-Gil; Ana I Rodriguez-Perez; Antonio Dominguez-Meijide; Maria J Guerra; Jose L Labandeira-Garcia
Journal:  Mol Neurobiol       Date:  2018-02-05       Impact factor: 5.590

Review 6.  Is Gut Dysbiosis an Epicenter of Parkinson's Disease?

Authors:  Charul Rajput; Alika Sarkar; Nidhi Sachan; Neeraj Rawat; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2021-01-05       Impact factor: 3.996

7.  Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Ganna Tolstanova; Xiaoming Deng; Amrita Ahluwalia; Brankica Paunovic; Alona Prysiazhniuk; Lyudmyla Ostapchenko; Andrzej Tarnawski; Zsuzsanna Sandor; Sandor Szabo
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

8.  Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.

Authors:  Laura L Dugan; LinLin Tian; Kevin L Quick; Josh I Hardt; Morvarid Karimi; Chris Brown; Susan Loftin; Hugh Flores; Stephen M Moerlein; John Polich; Samer D Tabbal; Jonathan W Mink; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2014-07-22       Impact factor: 10.422

9.  Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Authors:  Viviane Labrie; Patrik Brundin
Journal:  J Innate Immun       Date:  2017-09-02       Impact factor: 7.349

Review 10.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.